| Product NDC: | 52544-955 |
| Proprietary Name: | Fiorinal |
| Non Proprietary Name: | Butalbital, Aspirin, and Caffeine |
| Active Ingredient(s): | 325; 50; 40 mg/1; mg/1; mg/1 & nbsp; Butalbital, Aspirin, and Caffeine |
| Administration Route(s): | ORAL |
| Dosage Form(s): | CAPSULE |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 52544-955 |
| Labeler Name: | Watson Pharma, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA017534 |
| Marketing Category: | NDA |
| Start Marketing Date: | 19760504 |
| Package NDC: | 52544-955-01 |
| Package Description: | 100 CAPSULE in 1 BOTTLE (52544-955-01) |
| NDC Code | 52544-955-01 |
| Proprietary Name | Fiorinal |
| Package Description | 100 CAPSULE in 1 BOTTLE (52544-955-01) |
| Product NDC | 52544-955 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Butalbital, Aspirin, and Caffeine |
| Dosage Form Name | CAPSULE |
| Route Name | ORAL |
| Start Marketing Date | 19760504 |
| Marketing Category Name | NDA |
| Labeler Name | Watson Pharma, Inc. |
| Substance Name | ASPIRIN; BUTALBITAL; CAFFEINE |
| Strength Number | 325; 50; 40 |
| Strength Unit | mg/1; mg/1; mg/1 |
| Pharmaceutical Classes | Barbiturate [EPC],Barbiturates [Chemical/Ingredient],Cyclooxygenase Inhibitors [MoA],Decreased Prostaglandin Production [PE],Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient],Nonsteroidal Anti-inflammatory Drug [EPC],Central Nervous System Stimulant [EPC],Central Nervous System Stimulation [PE],Methylxanthine [EPC],Xanthines [Chemical/Ingredient] |